{"pmid":32274617,"title":"SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.","text":["SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.","SARS-CoV-2 virus, the causative agent of the coronavirus infectious disease-19 (COVID-19), is taking the globe by storm, approaching 500,000 confirmed cases and over 21,000 deaths as of March 25, 2020. While under control in some affected Asian countries (Taiwan, Singapore, Vietnam), the virus demonstrated an exponential phase of infectivity in several large countries (China in late January and February and many European countries and the USA in March), with cases exploding by 30-50,000/day in the third and fourth weeks of March, 2020. SARS-CoV-2 has proven to be particularly deadly to older adults and those with certain underlying medical conditions, many of whom are of advanced age. Here, we briefly review the virus, its structure and evolution, epidemiology and pathogenesis, immunogenicity and immune, and clinical response in older adults, using available knowledge on SARS-CoV-2 and its highly pathogenic relatives MERS-CoV and SARS-CoV-1. We conclude by discussing clinical and basic science approaches to protect older adults against this disease.","Geroscience","Nikolich-Zugich, Janko","Knox, Kenneth S","Rios, Carlos Tafich","Natt, Bhupinder","Bhattacharya, Deepta","Fain, Mindy J","32274617"],"abstract":["SARS-CoV-2 virus, the causative agent of the coronavirus infectious disease-19 (COVID-19), is taking the globe by storm, approaching 500,000 confirmed cases and over 21,000 deaths as of March 25, 2020. While under control in some affected Asian countries (Taiwan, Singapore, Vietnam), the virus demonstrated an exponential phase of infectivity in several large countries (China in late January and February and many European countries and the USA in March), with cases exploding by 30-50,000/day in the third and fourth weeks of March, 2020. SARS-CoV-2 has proven to be particularly deadly to older adults and those with certain underlying medical conditions, many of whom are of advanced age. Here, we briefly review the virus, its structure and evolution, epidemiology and pathogenesis, immunogenicity and immune, and clinical response in older adults, using available knowledge on SARS-CoV-2 and its highly pathogenic relatives MERS-CoV and SARS-CoV-1. We conclude by discussing clinical and basic science approaches to protect older adults against this disease."],"journal":"Geroscience","authors":["Nikolich-Zugich, Janko","Knox, Kenneth S","Rios, Carlos Tafich","Natt, Bhupinder","Bhattacharya, Deepta","Fain, Mindy J"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274617","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s11357-020-00186-0","keywords":["COVID-19","Care","Immunity","Older adults","Pathogenesis","SARS-CoV-2"],"source":"PubMed","locations":["China","Singapore","Vietnam","China","USA"],"countries":["United States","China","Viet Nam","Singapore"],"countries_codes":["USA|United States","CHN|China","VNM|Viet Nam","SGP|Singapore"],"topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1663712077878919169,"score":7.9164424,"similar":[{"pmid":32255507,"title":"COVID-19 And Older Adults: What We Know.","text":["COVID-19 And Older Adults: What We Know.","SARS-CoV-2, a novel virus that causes COVID-19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease. A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and chronic kidney disease are placed on angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Studies have shown that these medications upregulate the ACE-2 receptor, the very receptor which the SARS-CoV-2 virus uses to enter host cells, which puts older adults at a further increased risk of infection. In this review, we discuss the transmission, symptomatology, mortality, and possible treatments for this infection, as they relate to older adults. This article is protected by copyright. All rights reserved.","J Am Geriatr Soc","Shahid, Zainab","Kalayanamitra, Ricci","McClafferty, Brendan","Kepko, Douglas","Ramgobin, Devyani","Patel, Ravi","Aggarwal, Chander Shekher","Vunnam, Rama Rao","Sahu, Nitasa","Bhatt, Dhirisha","Jones, Kirk","Golamari, Reshma","Jain, Rohit","32255507"],"abstract":["SARS-CoV-2, a novel virus that causes COVID-19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease. A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and chronic kidney disease are placed on angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Studies have shown that these medications upregulate the ACE-2 receptor, the very receptor which the SARS-CoV-2 virus uses to enter host cells, which puts older adults at a further increased risk of infection. In this review, we discuss the transmission, symptomatology, mortality, and possible treatments for this infection, as they relate to older adults. This article is protected by copyright. All rights reserved."],"journal":"J Am Geriatr Soc","authors":["Shahid, Zainab","Kalayanamitra, Ricci","McClafferty, Brendan","Kepko, Douglas","Ramgobin, Devyani","Patel, Ravi","Aggarwal, Chander Shekher","Vunnam, Rama Rao","Sahu, Nitasa","Bhatt, Dhirisha","Jones, Kirk","Golamari, Reshma","Jain, Rohit"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32255507","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jgs.16472","keywords":["COVID-19","Coronavirus","Mortality","Older Adults","SARS-CoV-2"],"source":"PubMed","locations":["American"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Transmission","Diagnosis","Treatment"],"weight":1,"_version_":1663450393559957504,"score":303.74875},{"pmid":32214079,"title":"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020.","text":["Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020.","Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries (1). On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic (2). Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19-associated illness and death than are younger persons (3). Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged >/=60 years; only one (0.1%) death occurred in a person aged </=19 years (3). In this report, COVID-19 cases in the United States that occurred during February 12-March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group. As of March 16, a total of 4,226 COVID-19 cases in the United States had been reported to CDC, with multiple cases reported among older adults living in long-term care facilities (4). Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged >/=65 years with the highest percentage of severe outcomes among persons aged >/=85 years. In contrast, no ICU admissions or deaths were reported among persons aged </=19 years. Similar to reports from other countries, this finding suggests that the risk for serious disease and death from COVID-19 is higher in older age groups.","MMWR Morb Mortal Wkly Rep","32214079"],"abstract":["Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries (1). On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic (2). Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19-associated illness and death than are younger persons (3). Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged >/=60 years; only one (0.1%) death occurred in a person aged </=19 years (3). In this report, COVID-19 cases in the United States that occurred during February 12-March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group. As of March 16, a total of 4,226 COVID-19 cases in the United States had been reported to CDC, with multiple cases reported among older adults living in long-term care facilities (4). Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged >/=65 years with the highest percentage of severe outcomes among persons aged >/=85 years. In contrast, no ICU admissions or deaths were reported among persons aged </=19 years. Similar to reports from other countries, this finding suggests that the risk for serious disease and death from COVID-19 is higher in older age groups."],"journal":"MMWR Morb Mortal Wkly Rep","date":"2020-03-28T11:00:00Z","year":2020,"_id":"32214079","week":"202013|Mar 23 - Mar 29","doi":"10.15585/mmwr.mm6912e2","source":"PubMed","locations":["United States","China","- United States"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1663352134958055425,"score":244.7575},{"pmid":32169119,"pmcid":"PMC7068984","title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","text":["The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to beta-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.","Mil Med Res","Guo, Yan-Rong","Cao, Qing-Dong","Hong, Zhong-Si","Tan, Yuan-Yang","Chen, Shou-Deng","Jin, Hong-Jun","Tan, Kai-Sen","Wang, De-Yun","Yan, Yan","32169119"],"abstract":["An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to beta-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus."],"journal":"Mil Med Res","authors":["Guo, Yan-Rong","Cao, Qing-Dong","Hong, Zhong-Si","Tan, Yuan-Yang","Chen, Shou-Deng","Jin, Hong-Jun","Tan, Kai-Sen","Wang, De-Yun","Yan, Yan"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32169119","week":"202011|Mar 09 - Mar 15","doi":"10.1186/s40779-020-00240-0","keywords":["*Clinical characteristics","*Coronavirus disease 2019 (COVID-19)","*Origin","*SARS-CoV-2","*Therapy","*Transmission"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment","Transmission"],"weight":1,"_version_":1663352133982879744,"score":234.85994},{"pmid":32267987,"title":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.","text":["Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.","The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future.","Rev Med Virol","Rokni, Mohsen","Ghasemi, Vida","Tavakoli, Zahra","32267987"],"abstract":["The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future."],"journal":"Rev Med Virol","authors":["Rokni, Mohsen","Ghasemi, Vida","Tavakoli, Zahra"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267987","week":"202015|Apr 06 - Apr 12","doi":"10.1002/rmv.2107","keywords":["2019-nCoV disease","B cell","COVID-19","SARS-CoV-2","T cell","coronavirus","immunity"],"source":"PubMed","locations":["Iran","China"],"countries":["China","Iran, Islamic Republic of"],"countries_codes":["CHN|China","IRN|Iran, Islamic Republic of"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663609715714686976,"score":234.53677},{"pmid":32270184,"title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19.","text":["Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging coronavirus that has resulted in nearly 1,000,000 laboratory-confirmed cases including over 50,000 deaths. Although SARS-CoV-2 and SARS-CoV share a number of common clinical manifestations, SARS-CoV-2 appears to be highly efficient in person-to-person transmission and frequently cause asymptomatic infections. However, the underlying mechanism that confers these viral characteristics on high transmissibility and asymptomatic infection remain incompletely understood. METHODS: We comprehensively investigated the replication, cell tropism, and immune activation profile of SARS-CoV-2 infection in human lung tissues with SARS-CoV included as a comparison. RESULTS: SARS-CoV-2 infected and replicated in human lung tissues more efficiently than that of SARS-CoV. Within the 48-hour interval, SARS-CoV-2 generated 3.20 folds more infectious virus particles than that of SARS-CoV from the infected lung tissues (P<0.024). SARS-CoV-2 and SARS-CoV were similar in cell tropism, with both targeting types I and II pneumocytes, and alveolar macrophages. Importantly, despite the more efficient virus replication, SARS-CoV-2 did not significantly induce types I, II, or III interferons in the infected human lung tissues. In addition, while SARS-CoV infection upregulated the expression of 11 out of 13 (84.62%) representative pro-inflammatory cytokines/chemokines, SARS-CoV-2 infection only upregulated 5 of these 13 (38.46%) key inflammatory mediators despite replicating more efficiently. CONCLUSIONS: Our study provided the first quantitative data on the comparative replication capacity and immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung tissues. Our results provided important insights on the pathogenesis, high transmissibility, and asymptomatic infection of SARS-CoV-2.","Clin Infect Dis","Chu, Hin","Chan, Jasper Fuk-Woo","Wang, Yixin","Yuen, Terrence Tsz-Tai","Chai, Yue","Hou, Yuxin","Shuai, Huiping","Yang, Dong","Hu, Binjie","Huang, Xiner","Zhang, Xi","Cai, Jian-Piao","Zhou, Jie","Yuan, Shuofeng","Kok, Kin-Hang","To, Kelvin Kai-Wang","Chan, Ivy Hau-Yee","Zhang, Anna Jinxia","Sit, Ko-Yung","Au, Wing-Kuk","Yuen, Kwok-Yung","32270184"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging coronavirus that has resulted in nearly 1,000,000 laboratory-confirmed cases including over 50,000 deaths. Although SARS-CoV-2 and SARS-CoV share a number of common clinical manifestations, SARS-CoV-2 appears to be highly efficient in person-to-person transmission and frequently cause asymptomatic infections. However, the underlying mechanism that confers these viral characteristics on high transmissibility and asymptomatic infection remain incompletely understood. METHODS: We comprehensively investigated the replication, cell tropism, and immune activation profile of SARS-CoV-2 infection in human lung tissues with SARS-CoV included as a comparison. RESULTS: SARS-CoV-2 infected and replicated in human lung tissues more efficiently than that of SARS-CoV. Within the 48-hour interval, SARS-CoV-2 generated 3.20 folds more infectious virus particles than that of SARS-CoV from the infected lung tissues (P<0.024). SARS-CoV-2 and SARS-CoV were similar in cell tropism, with both targeting types I and II pneumocytes, and alveolar macrophages. Importantly, despite the more efficient virus replication, SARS-CoV-2 did not significantly induce types I, II, or III interferons in the infected human lung tissues. In addition, while SARS-CoV infection upregulated the expression of 11 out of 13 (84.62%) representative pro-inflammatory cytokines/chemokines, SARS-CoV-2 infection only upregulated 5 of these 13 (38.46%) key inflammatory mediators despite replicating more efficiently. CONCLUSIONS: Our study provided the first quantitative data on the comparative replication capacity and immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung tissues. Our results provided important insights on the pathogenesis, high transmissibility, and asymptomatic infection of SARS-CoV-2."],"journal":"Clin Infect Dis","authors":["Chu, Hin","Chan, Jasper Fuk-Woo","Wang, Yixin","Yuen, Terrence Tsz-Tai","Chai, Yue","Hou, Yuxin","Shuai, Huiping","Yang, Dong","Hu, Binjie","Huang, Xiner","Zhang, Xi","Cai, Jian-Piao","Zhou, Jie","Yuan, Shuofeng","Kok, Kin-Hang","To, Kelvin Kai-Wang","Chan, Ivy Hau-Yee","Zhang, Anna Jinxia","Sit, Ko-Yung","Au, Wing-Kuk","Yuen, Kwok-Yung"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270184","week":"202015|Apr 06 - Apr 12","doi":"10.1093/cid/ciaa410","keywords":["ex vivo","COVID-19","SARS-CoV-2","coronavirus","interferon"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663620083096748032,"score":210.21776}]}